These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29429971)

  • 21. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
    Rinne JO; Brooks DJ; Rossor MN; Fox NC; Bullock R; Klunk WE; Mathis CA; Blennow K; Barakos J; Okello AA; Rodriguez Martinez de Liano S; Liu E; Koller M; Gregg KM; Schenk D; Black R; Grundman M
    Lancet Neurol; 2010 Apr; 9(4):363-72. PubMed ID: 20189881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
    Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
    JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study.
    Manca C; Rivasseau Jonveaux T; Roch V; Marie PY; Karcher G; Lamiral Z; Malaplate C; Verger A
    J Neurol; 2019 Jul; 266(7):1685-1692. PubMed ID: 30963253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
    Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P
    Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.
    Babulal GM; Ghoshal N; Head D; Vernon EK; Holtzman DM; Benzinger TLS; Fagan AM; Morris JC; Roe CM
    Am J Geriatr Psychiatry; 2016 Nov; 24(11):1095-1104. PubMed ID: 27426238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.
    Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P
    J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab.
    Nisenbaum L; Martone R; Chen T; Rajagovindan R; Dent G; Beaver J; Rubel C; Racine A; He P; Harrison K; Dean R; Vandijck M; Haeberlein SB
    Alzheimers Dement; 2023 Aug; 19(8):3379-3388. PubMed ID: 36795603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
    Lewczuk P; Matzen A; Blennow K; Parnetti L; Molinuevo JL; Eusebi P; Kornhuber J; Morris JC; Fagan AM
    J Alzheimers Dis; 2017; 55(2):813-822. PubMed ID: 27792012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation.
    Skouras S; Torner J; Andersson P; Koush Y; Falcon C; Minguillon C; Fauria K; Alpiste F; Blenow K; Zetterberg H; Gispert JD; Molinuevo JL;
    Brain; 2020 Mar; 143(3):976-992. PubMed ID: 32091109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.
    Liu E; Schmidt ME; Margolin R; Sperling R; Koeppe R; Mason NS; Klunk WE; Mathis CA; Salloway S; Fox NC; Hill DL; Les AS; Collins P; Gregg KM; Di J; Lu Y; Tudor IC; Wyman BT; Booth K; Broome S; Yuen E; Grundman M; Brashear HR;
    Neurology; 2015 Aug; 85(8):692-700. PubMed ID: 26208959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease.
    Jack CR; Vemuri P; Wiste HJ; Weigand SD; Lesnick TG; Lowe V; Kantarci K; Bernstein MA; Senjem ML; Gunter JL; Boeve BF; Trojanowski JQ; Shaw LM; Aisen PS; Weiner MW; Petersen RC; Knopman DS;
    Arch Neurol; 2012 Jul; 69(7):856-67. PubMed ID: 22409939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
    Delnomdedieu M; Duvvuri S; Li DJ; Atassi N; Lu M; Brashear HR; Liu E; Ness S; Kupiec JW
    Alzheimers Res Ther; 2016 Mar; 8(1):12. PubMed ID: 26925577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers.
    Roe CM; Ances BM; Head D; Babulal GM; Stout SH; Grant EA; Hassenstab J; Xiong C; Holtzman DM; Benzinger TLS; Schindler SE; Fagan AM; Morris JC
    Brain; 2018 Nov; 141(11):3233-3248. PubMed ID: 30304397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study.
    Xiong C; Jasielec MS; Weng H; Fagan AM; Benzinger TL; Head D; Hassenstab J; Grant E; Sutphen CL; Buckles V; Moulder KL; Morris JC
    Neurology; 2016 Apr; 86(16):1499-506. PubMed ID: 27009258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serial MRI and CSF biomarkers in normal aging, MCI, and AD.
    Vemuri P; Wiste HJ; Weigand SD; Knopman DS; Trojanowski JQ; Shaw LM; Bernstein MA; Aisen PS; Weiner M; Petersen RC; Jack CR;
    Neurology; 2010 Jul; 75(2):143-51. PubMed ID: 20625167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
    Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
    Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
    J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.
    Schindler SE; Gray JD; Gordon BA; Xiong C; Batrla-Utermann R; Quan M; Wahl S; Benzinger TLS; Holtzman DM; Morris JC; Fagan AM
    Alzheimers Dement; 2018 Nov; 14(11):1460-1469. PubMed ID: 29501462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report.
    Schroeter ML; Tiepolt S; Marschhauser A; Thöne-Otto A; Hoffmann KT; Barthel H; Obrig H; Sabri O
    BMC Neurol; 2015 Aug; 15():152. PubMed ID: 26303364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimer's disease.
    Jaillard A; Vanhoutte M; Maureille A; Schraen S; Skrobala E; Delbeuck X; Rollin-Sillaire A; Pasquier F; Bombois S; Semah F
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):324-333. PubMed ID: 30155553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.